BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

BioMarin Pharmaceutical is well-positioned in the rare genetic disease market with a diverse portfolio of approved therapies and a promising pipeline of potential treatments. The recent settlement with Ascendis Pharma for its competing therapy YUVIWEL reduces the risk of market share loss for BioMarin's VOXZOGO and provides the company with a steady stream of revenue through 2030. The convenience difference between YUVIWEL's once-weekly injection and VOXZOGO's daily injection could make it a more attractive option for caregivers of young children, potentially leading to increased uptake. Additionally, BioMarin has other potential catalysts in the near future, such as the FDA review of a supplemental New Drug Application for one of its therapies, providing potential for stock growth in the coming years.

BioMarin Pharmaceutical is expected to have a positive outlook following the settlement of their Voxzogo litigation and monetization of their intellectual property. This will provide a clearer path for their broader thesis focusing on the integration of Amicus and pipeline expansion, leading to an increased FY27E EPS and an increase in their target price to $90/share. It should be noted that the company changed their non-GAAP accounting methodology, which has been adjusted for past and future estimates.